发明名称 Dosage Regime for Apolipoprotein Formulations
摘要 An apolipoprotein formulation is provided at a fixed dosage that is efficacious in the prophylactic and/or therapeutic treatment of diseases or conditions including, but not limited to cardiovascular disease, acute coronary syndrome, atherosclerosis, unstable angina pectoris, and myocardial infarction. More particularly, the fixed dosage apolipoprotein formulation displays relatively reduced inter-patient variability compared to weight-adjusted dosages. Typically, the apolipoprotein formulation is a reconstituted high density lipoprotein formulation comprising ApoA1, one or more lipids such as phosphatidylcholine, sphingomyelin and/or phosphatidylglycerol and, optionally, a detergent such as cholate at a level that does not induce liver toxicity.
申请公布号 US2014378376(A1) 申请公布日期 2014.12.25
申请号 US201214364764 申请日期 2012.11.02
申请人 CSL Limited 发明人 Rayner Craig
分类号 A61K38/17;A61K45/06 主分类号 A61K38/17
代理机构 代理人
主权项 1. A method of prophylactically or therapeutically treating a disease, disorder or condition in a human including the step of administering to the human a fixed dosage apolipoprotein formulation, to thereby treat said disease, disorder or condition in the human.
地址 Parkville, Victoria AU